Amarin stock posts 9% decline in Q1 topline amid generic competition

Amarin Company (NASDAQ:AMRN) reported higher than anticipated financials for Q1 2023 on Wednesday, at the same time as its topline contracted ~9% YoY amid generic competitors to its fish oil-derived coronary heart illness remedy Vazkepa.

The Eire-based biotech posted $86.0M in complete income whereas its web product income fell ~10% YoY to $84.7M as generic competitors damage quantity and web promoting value within the U.S., the place web product income witnessed a ~7% sequential drop.

“Whereas we’ll proceed to work to optimally handle the U.S. enterprise, I’m targeted with the group on methods to speed up affected person entry and income in Europe,” interim CEO Aaron Berg remarked.

Nevertheless, regardless of a decline in gross margin from 76% in Q1 2022 to 70% adjusted for a one-off cost, the corporate’s GAAP web loss for the quarter dipped ~48% YoY to $16.5M as SG&A bills fell ~34% YoY to $59.6M amid ongoing cost-saving efforts.

Citing extra value reductions and timing of reimbursements, Amarin (AMRN) lowered its full-year outlook for working bills to $270M – $285M from $290M – $305M within the earlier forecast.

Extra on Amarin

• Amarin 8% greater after Sarissa wins proxy battle with administration
• Amarin: Sarissa Has Management, However Amarin Will Want Persistence